Fostamatinib: Warm Autoimmune Hemolytic Anemia
A Phase 3, open-label, extension study of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia.
Phase 3 – wAIHA
Fostamatinib: COVID-19
A Phase 3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study to evaluate the safety and efficacy of fostamatinib in patients with COVID-19.
Phase 3 - COVID-19R289: Lower-risk Myelodysplastic Syndromes
A Phase 1b, open-label study to determine tolerability and preliminary efficacy of R289 in patients with Lower-risk Myelodysplastic Syndromes (LR-MDS).
Phase 1b – LR-MDS